Subtype-specific reprogramming of astrocytes for precision drug screening
A novel platform leveraging astrocyte-specific enhancers to identify and characterize disease-relevant astrocyte subtypes, enhancing Alzheimer's drug screening precision.
Overview
This innovative solution leverages astrocyte-specific enhancer usage patterns to identify and characterize disease-relevant astrocyte subtypes, significantly enhancing the precision of Alzheimer's disease (AD) drug screening. By exploiting the unique gene expression signatures of astrocytes linked to amyloid and tau pathologies, this approach enables the selective reprogramming of astrocytes to serve as reliable platforms for drug discovery.
Technical specifications
Key Features:
- Utilizes cell-type-specific enhancers within adeno-associated viruses (AAVs) for efficient targeting of astrocyte subtypes.
- Employs high-throughput sequencing techniques such as scATAC-seq and scRNA-seq to identify distinct astrocyte subtypes and their associated enhancers.
- Demonstrates cost-effective targeting across various mammalian species, enhancing the versatility of the platform.
Applications:
- Identification and characterization of astrocyte subtypes in Alzheimer's disease.
- Drug discovery and screening platform, allowing for precision targeting of disease-relevant astrocyte populations.
Technology readiness level
This technology is currently at Technology Readiness Level (TRL) 2, with initial validation efforts underway. Future steps include confirming enhancer specificity and establishing proof of concept for drug screening using reprogrammed astrocytes.
About Michigan State University
Michigan State University is a major public land‑grant research university with a comprehensive academic portfolio and a large research enterprise. Industry partners engage through an on‑campus U.S. Department of Energy national user facility and shared core laboratories with user access. The university provides a chemical process scale‑up pilot plant on Michigan’s lakeshore, a research and technology park, and a Grand Rapids health innovation campus linking researchers with clinical partners. A statewide extension network supports field deployment and workforce training across Michigan’s manufacturing corridor. Research is backed by competitive federal funding from NSF, NIH, DOE, USDA, and DoD, while dedicated tech transfer and corporate engagement teams—supported by an affiliated research foundation—accelerate IP, licensing, startups, and sponsored research.
Inquire about this partnering listing
Industry applications
delivered to your inbox.